Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Copper Miners ETF (COPX) vs Cassava Sciences Inc (FLNA) Price & Performance

Global X Copper Miners ETFTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Global X Copper Miners ETF vs Cassava Sciences Inc — how do they compare? Global X Copper Miners ETF trades at $77.21, while Cassava Sciences Inc trades at $1.11 (market cap $52.66M). The key difference: Global X Copper Miners ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

COPXFLNA
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$95.70$4.64
52-Week Low
$42.75$1.09
Market Cap
$52.66M
Enterprise Value
-$33.92M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Copper Miners ETF

COPX (Global X Copper Miners ETF) trades at $74.35, down 2.86% amid bearish technical signals with all 16 moving average indicators signaling sell. The ETF provides exposure to copper mining companies benefiting from AI-driven electrification demand, though key financial ratios remain undisclosed in current data. Recent news highlights copper's structural role in AI infrastructure and energy transition.

Outlook hinges on copper supply-demand dynamics amplified by AI data center expansion, though technical weakness suggests near-term pressure. Risks include commodity price volatility and execution challenges in mining supply chains. Analyst sentiment remains constructive on long-term copper fundamentals despite current bearish technical positioning.

Cassava Sciences Inc

FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.

Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Copper Miners ETF

COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.

Read more on COPX

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA